Brands Browse Interactions Pill ID Categories

Loading…

Drugvu is an independent compilation of publicly-disclosed pharmaceutical regulatory information. It is not affiliated with the FDA, EMA, MHRA, Health Canada, TGA, TİTCK, PMDA, or any pharmaceutical manufacturer or regulatory agency.

This is not medical advice. Always consult a qualified healthcare professional for medical decisions.

About Editorial process Editorial team Data sources Methodology Corrections Contribute Privacy Terms DMCA Contact

Certolizumab Pegol and Ibritumomab Tiuxetan: Major Interaction - Drugvu

🏠›Certolizumab Pegol›Interaction with Ibritumomab Tiuxetan

Certolizumab Pegol + Ibritumomab Tiuxetan

Drug interaction

Major interaction

A major drug-drug interaction between Certolizumab Pegol and Ibritumomab Tiuxetan is recorded in public interaction data. Severity reflects the source classification; it does not describe your individual risk. Do not start, stop, or change either medicine based on this page.

What “major” means

A major interaction can cause a clinically significant - sometimes serious - effect. Prescribers usually avoid this combination, or use it only with close monitoring and dose adjustments.

What to do

Do not combine these on your own. If both have been prescribed, tell your pharmacist or doctor so they can confirm it is intended and watch for problems.

The two medicines

Active ingredient

Certolizumab Pegol

Tumor Necrosis Factor Alpha (Tnf-Alpha) Inhibitors

Uses, side effects, dosage →· 308 recorded interactions

Active ingredient

Ibritumomab Tiuxetan

Uses, side effects, dosage →· 151 recorded interactions

Source

DDInter 2.0 (CC-BY 4.0, https://ddinter.scbdd.com)

This is not medical advice. Drugvu is an independent aggregator of public records.